NAD+ vs MOTS-c: What the Research Shows
NAD+ and MOTS-c side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider NAD+ if…
- you want a systematic review of the field: for NAD+ supplementation, clinical effectiveness for anti-aging or wellness outcomes remains inconclusive[13]
- you want to know about intravenous use: the systematic review found no eligible outcomes trials of intravenous or intramuscular NAD+ for anti-aging or wellness[13]
- you want real-world IV data: in a retrospective pilot of commercial infusions, NAD+ IV was associated with moderate to severe gastrointestinal symptoms, higher heart rate and chest pressure[14]
Consider MOTS-c if…
- you are weighing human evidence that, in our search, only measured the body's own MOTS-c (none gave it as a treatment): exercise raised plasma MOTS-c in non-Hispanic White survivors but not Hispanic survivors[6]
Spec comparison
Showing 10 of 10 fields where the two differ.
| Field | NAD+ | MOTS-c |
|---|---|---|
| Class | Coenzyme (injectable, IV or nasal) | Mitochondrial-derived peptide |
| Also called | NAD, nicotinamide adenine dinucleotide | mots |
| FDA status | Compounded | PCAC voted 7–5 for 503A (Jul 2026) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | PCAC voted 7–5 for the 503A list (Jul 2026); not finalized |
| WADA | No WADA record in our data | Prohibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | [half-life by route] | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | [evidence grade] | Human RCT evidence, 4 of 4Strongest: Medicine and science in sports and exercise 2025, PMID 40674654 |
| Human studies we summarised | [n] | 7 human (4 randomized or controlled) of 15 summarised |
| Typical study doses | [dose range] |
|
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Both lean on animal data, but in different ways
In rodent models, NAD+ augmentation was frequently associated with improvements in metabolic, mitochondrial, inflammatory and functional outcomes, though effects varied across models and endpoints.[13]
In a mouse paper, MOTS-c improved physical performance across three age groups: young, middle-aged and old.[17]
The same paper notes that in humans, exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation.[17]
In humans, oral NR and NMN consistently demonstrated biochemical target engagement.[13]
The NAD+ review found no eligible outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness indications.[13]
Regulation, sport and tolerability
WADA lists MOTS-c in the AMPK-activator group, with BAM15 and AICAR.[2]
Drugs@FDA has no MOTS-c entry: the search returned no match.[18]
In a clinic record review, participants receiving NAD+ IV reported moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during infusions.[14]
The authors of that review say additional studies are needed to evaluate dosage and effectiveness beyond 30 days.[14]
Common questions
Is NAD or MOTS-c better for energy and mitochondria?
The NAD+ review concluded that NAD+ augmentation shows clear biological activity but clinical effectiveness for anti-aging or wellness outcomes remains inconclusive. MOTS-c's performance results in the cached sources are in mice.[13]
Can NAD and MOTS-c be stacked?
A PubMed search on 2 Oct 2026 for MOTS-c with NAD matched 2 records; none is recorded as a study of the pair.
Calculated from pubmed query ("MOTS-c"[tiab] OR MOTSc[tiab]) AND ("NAD+"[tiab] OR "nicotinamide adenine dinucleotide"[tiab]); records matched 2; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json (mots-c__nad) for the query on search_date
Is MOTS-c banned in sport?
Yes. WADA's prohibited list includes MOTS-c among AMPK activators.[2]
Sources
- 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
- 4Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
- 5Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
- 6Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
- 7PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND ("NAD+"[tiab] OR "nicotinamide adenine dinucleotide"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.Ageing research reviews · 2026PMID 41655607Accessed 2 Oct 2026
- 14Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting.Frontiers in aging · 2026PMID 41704678Accessed 2 Oct 2026
- 15Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 16PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 17MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.Nature communications · 2021PMID 33473109Accessed 2 Oct 2026
- 18Drugs@FDA (openFDA) search: active ingredient "MOTS-c"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.